AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 141 min read$GH

Kalia Kumud sold $632K of GH

Kalia Kumud (Chief Information Officer) sold 4,000 shares of Guardant Health, Inc. (GH) at $158.05 ($0.63M total) on 2026-09-11.

Original reporting
SEC EDGAR · Kalia Kumud
Published Sep 14, 2026, 10:11 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 14, 2026, 10:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The sale reduces insider ownership but does not change company fundamentals.

02

Market read

A routine insider sale with modest dollar value; limited trading relevance.

03

What to watch

Potential tax planning or liquidity needs for the insider; not necessarily a negative signal.

Relevance 5/10Novelty 8/10Timing: filing date 2026-09-14 (same‑day disclosure)

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Chief Information Officer sold 4,000 shares for $632,193, reducing his stake to 39,794 shares.

Expected impact

Potential short-term downward pressure on GH price.

Evidence & confidence

Sale size is modest ($0.6M) for a mid‑cap biotech; market may view it as routine but could trigger slight sell‑off.

Market effects

Sector

Minimal impact on biotech sector; insider sales are common.

Regional

None

Global

Low

Counterpoint

What could challenge this read

Sale could be unrelated to company outlook; may present a buying opportunity if fundamentals remain strong.

Key entities

  • Company
    Guardant Health, Inc.

    US‑listed biotech (ticker GH).

  • Insider
    Kalia Kumud

    Chief Information Officer of Guardant Health.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

GH insider trading history →

Related articles

OCT 20
$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

insidermonkey.com3 min
OCT 9
$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.

onclive.com6 min